Comparisons of baseline characteristics between the NRKFD and RKFD groups
| Parameters | NRKFD group (n=675） | RKFD group (n=179） | All patients (n=854) |
| Age (year)* | 57.1±11.73 | 57.8±11.34 | 57.2±11.64 |
| Age ≥65† | 175 (25.9) | 49 (27.4) | 224 (26.2) |
| Male† | 427 (63.3) | 126 (70.4) | 553 (64.8) |
| Course (year)‡ | 6 (3, 10) | 9 (4, 14)§ | 7 (3, 11) |
| Course ≥10† | 228 (33.8) | 86 (48.0)§ | 314 (36.8) |
| BMI (kg/m2)‡ | 24.82 (23.0, 26.8) | 24.69 (22.4, 26.9) | 24.8 (22.9, 26.8) |
| SBP (mm Hg)‡ | 130 (121, 140) | 135 (126, 150)§ | 130 (122, 142) |
| DBP (mm Hg)‡ | 78 (73, 84) | 79 (72, 84) | 78 (73, 84) |
| History of hypertension† | 336 (49.8) | 105 (58.7)§ | 441 (51.6) |
| TG (mmol/L)‡ | 1.67 (1.11, 2.59) | 1.80 (1.08, 3.07) | 1.67 (1.1, 2.66) |
| TC (mmol/L)‡ | 4.71 (4.1, 5.42) | 4.63 (3.84, 5.25) | 4.69 (4.0, 5.4) |
| LDL (mmol/L)‡ | 2.42 (1.9, 2.94) | 2.29 (1.75, 2.92) | 2.39 (1.9, 2.9) |
| HDL (mmol/L)‡ | 1.17 (1, 1.39) | 1.10 (0.92, 1.37)§ | 1.16 (0.98, 1.39) |
| UA (µmol/L)‡ | 290 (239.5, 344.5) | 317 (266.5, 387)§ | 296 (242, 353) |
| BUN (mmol/L)‡ | 5.17 (4.33, 6.25) | 5.59 (4.63, 6.82)§ | 5.27 (4.4, 6.3) |
| SCr (µmol/l)‡ | 67 (55, 79) | 71 (60, 84)§ | 68 (55, 79) |
| eGFR (mL/min/1.73 m2)‡ | 100.74 (85.4, 113.9) | 97.79 (77.0, 111.9)§ | 100.24 (83.8, 113.8) |
| UMAlb (mg/L)‡ | 18 (9, 42.2) | 102 (25.9, 323)§ | 21 (10, 57.8) |
| HbA1c (%)‡ | 8.4 (7.1, 10.2) | 9.2 (7.6, 11.3)§ | 8.6 (7.2, 10.4) |
| HbA1c ≥7† | 522 (77.3) | 152 (84.9)§ | 674 (78.9) |
| FBG (mmol/L)‡ | 7.7 (6.2, 9.8) | 8.3 (6.4, 10.2) | 7.8 (6.2, 9.8) |
| 2hPBG (mmol/L)‡ | 14.39 (11.1, 18.0) | 15.25 (12.0, 18.8) | 14.6 (11.2, 18.1) |
| FINS (uIU/mL)‡ | 7.63 (4.3, 12.6) | 7.55 (4.1, 12.4) | 7.57 (4.2, 12.6) |
| 2hPINS (uIU/mL)‡ | 28.10 (15.8, 52.6) | 21.07 (11.8, 39.0)§ | 26.88 (15.1, 49.3） |
| HOMA-β‡ | 36.99 (18.6, 68.6) | 35.28 (15.5, 67.2) | 36.07 (17.7, 68.3） |
| History of insulin treatment† | 584 (68.4) | 171 (20.0)§ | 755 (88.4) |
| FCP (ng/mL)‡ | 1.41 (0.88, 2.13) | 1.25 (0.77, 2.04) | 1.37 (0.9, 2.1) |
| FCGR‡ | 0.97 (0.59, 1.52) | 0.79 (0.47, 1.42)§ | 0.94 (0.6, 1.5) |
| 2hPCP (ng/mL)‡ | 3.50 (2.1, 5.3) | 2.63 (1.6, 4.3)§ | 3.34 (2.1, 5.2) |
| ΔCP (ng/mL)‡ | 2.02 (0.98, 3.58) | 1.42 (0.51, 2.61)§ | 1.9 (0.9, 3.3) |
| PCGR‡ | 1.39 (0.8, 2.36) | 0.91 (0.58, 1.71)§ | 1.29 (0.7, 2.2) |
*
.†N (%).
‡M (Q1, Q3).
§P<0.05 versus the NRKFD group.
BMI, body mass index; BUN, blood urea nitrogen; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; FCGR, fasting C-peptide-to-glucose ratio; FCP, fasting C-peptide; FINS, fasting insulin; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein cholesterol; HOMA-β, homeostatic model assessment of β-cell function; 2hPBG, 2-hour postprandial blood glucose; 2hPCP, 2-hour postprandial C-peptide; 2hPINS, 2-hour postprandial insulin; LDL, low-density lipoprotein cholesterol; NRKFD, non-rapid kidney function decline; PCGR, 2-hour postprandial C-peptide-to-glucose ratio; RKFD, rapid kidney function decline; SBP, systolic blood pressure; SCr, serum creatinine; TC, total cholesterol; TG, triglyceride; UA, uric acid; UMAlb, urine microalbumin; ΔCP, difference between 2-hour postprandial and fasting C-peptide.
